of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

COO — Perry A. Bernocchi: The Executive Vice President and Chief Operating Officer is ceasing to be an executive officer, representing the loss of a senior C-suite executive.

Entry into a Material Definitive Agreement. Amendment to Receivables Securitization Program On October 29, 2026, Accendra Funding LLC (“Accendra Funding”) and Byram Healthcare Centers, Inc. (“Byram”) each a wholly-owned subsidiary of Accendra Health, Inc., entered into the Third Amendment to the Amended & Restated Receivables Purchase Agreement (the “RPA Amendment”), which amends that certain Amended & Restated Receivables Purchase Agreement, dated as of December 31, 2025, as amended, by and…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 27, 2026, Accendra Health, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE’s Listed Company Manual (“Section 802.01B”) that the Company have an average market capitalization of not less than $50.0 million over a consecutive 30 t…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 6, 2026 Accendra Health, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s Common Stock (the “Common Stock”) was less than $1.00 per sh…

CEO — Edward A. Pesicka: The CEO is retiring with a pre-announced successor and a consulting transition plan, indicating an orderly succession rather than a sudden loss of leadership.

CEO — Kenneth Gardner-Smith: The filing announces the planned retirement of the sitting CEO and the appointment of a named internal successor, representing an orderly succession rather than a sudden loss of leadership.

Entry into a Material Definitive Agreement. The board of directors (the “Board of Directors”) of Accendra Health, Inc. (the “Company”) has taken actions to facilitate the Company’s ability to preserve its net operating losses (“NOLs”) and certain other tax attributes. In connection therewith, on August 9, 2026, the Board of Directors declared a dividend of one preferred share purchase right (a “Right”) for each share of Common Stock, par value $ 2.00 per share, of the Company (the “Common Sha…

CEO — Edward A. Pesicka: The CEO announced a planned retirement with a stated intention to step down by end of 2026 or upon successor appointment, indicating an orderly succession rather than a sudden loss.

Material Modifications to Rights of Security Holders. The information set forth in Items 1.01 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

by reference. New Notes Indentures and New Notes Overview The First Lien Notes issued as part of the new money issuance and delivered in exchange for the 2029 Notes tendered prior to the Early Exchange Time were issued pursuant to the Indenture, dated June 15, 2026 (the “First Lien Indenture”), by and among the Company, the guarantors named therein and Regions Bank, as trustee (in such capacity, the “First Lien Trustee”) and as collateral agent (in such capacity, the “First Lien Collateral Ag…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in the Explanatory Note and in

Other Events. On June 10, 2026, the Company issued a press release announcing the early results of the Exchange Offers and Consent Solicitations, which is filed hereto as Exhibit 99.1 and incorporated by reference herein. Cautionary Note Regarding the Exchange Offers The Exchange Offers are subject to the satisfaction or waiver of a number of conditions. The Company reserves the right, in its sole discretion, to amend the terms of the Exchange Offers. The Exchange Offers may not be completed…

of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act ”), except as shall be expressly set forth by specific reference in such…

The filing describes an amendment to the company's incentive plan, which is a routine corporate action.

of Form 8-K. The investor presentation includes certain information previously shared with the Commitment Parties during the course of the discussions preceding the execution of the Commitment Letter. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be…

Entry into a Material Definitive Agreement. On May 11, 2026, Accendra Health, Inc. (the “ Company ”) entered into a Commitment and Consent Letter (the “ Commitment Letter ”) with certain institutions that are (a)(i) holders of the Company’s 4.500% Senior Notes due 2029 (the “ 2029 Notes ”) and 6.625% Senior Notes due 2030 (the “ 2030 Notes ” and, together with the 2029 Notes, the “ Existing Notes ”), collectively holding approximately all of the outstanding principal amount of the 2029 Notes…

of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Executive Vice President, Chief Executive Officer, Products & Healthcare Services; Senior Vice President, Corporate Controller & Chief Accounting Officer — Andrew G. Long; Michael W. Lowry: Two senior executives, Andrew G. Long and Michael W. Lowry, departed the company in connection with the Transactions.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On the Closing Date, the Company entered into the Amended & Restated Receivables Purchase Agreement, the Purchase and Sale Agreement and the Performance Guaranty as described in

by reference. Completion of P&HS Sale On the Closing Date, pursuant to the terms of the Purchase Agreement, the Transactions (as defined below) were consummated, as a result of which the Company’s P&HS business was sold to the Purchaser and Purchaser Parent. Pursuant to the Purchase Agreement, upon the terms and subject to the conditions thereof, the Company (i) sold and transferred to Purchaser all of the Company’s right, title and interest in and to all of the issued and outstanding limited…

Entry into a Material Definitive Agreement. On the Closing Date, O&M Funding LLC (“ O&M Funding ”), as Seller, and Byram Healthcare Centers, Inc. (“ Byram ”), as initial Servicer, each a wholly-owned subsidiary of the Company, entered into an Amended & Restated Receivables Purchase Agreement (the “ Amended & Restated Receivables Purchase Agreement ”) with persons from time to time party thereto, as Purchasers, PNC Bank, National Association (“ PNC ”), as Administrative Agent, and PNC Capital…

The company froze participation and contributions under the Executive Deferred Compensation and Retirement Plan.